Spruce Biosciences (SPRB) Competitors

$56.50 -0.07 (-0.12%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$56.37 -0.13 (-0.23%)

As of 05/8/2026 07:46 PM Eastern

SPRB vs. RZLT, AVXL, GLSI, ACIU, and AMRN

Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Rezolute (RZLT), Anavex Life Sciences (AVXL), Greenwich LifeSciences (GLSI), AC Immune (ACIU), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

How does Spruce Biosciences compare to Rezolute?

Rezolute (NASDAQ:RZLT) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Rezolute currently has a consensus target price of $8.00, suggesting a potential upside of 149.22%. Spruce Biosciences has a consensus target price of $190.60, suggesting a potential upside of 237.35%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Rezolute has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.26, suggesting that its stock price is 226% more volatile than the S&P 500.

Rezolute's return on equity of -64.81% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-64.81%	-59.37%
Spruce Biosciences	N/A	-203.99%	-127.96%

In the previous week, Rezolute and Rezolute both had 1 articles in the media. Spruce Biosciences' average media sentiment score of 0.46 beat Rezolute's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spruce Biosciences has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$74.41M	-$0.93	N/A
Spruce Biosciences	$4.91M	15.76	-$38.97M	-$51.72	N/A

83.0% of Rezolute shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Spruce Biosciences beats Rezolute on 8 of the 13 factors compared between the two stocks.

How does Spruce Biosciences compare to Anavex Life Sciences?

Spruce Biosciences (NASDAQ:SPRB) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Spruce Biosciences currently has a consensus target price of $190.60, suggesting a potential upside of 237.35%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 562.53%. Given Anavex Life Sciences' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Spruce Biosciences has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	15.76	-$38.97M	-$51.72	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

In the previous week, Anavex Life Sciences had 8 more articles in the media than Spruce Biosciences. MarketBeat recorded 9 mentions for Anavex Life Sciences and 1 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.46 beat Anavex Life Sciences' score of 0.31 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anavex Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anavex Life Sciences' return on equity of -38.76% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-203.99%	-127.96%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Spruce Biosciences has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Spruce Biosciences beats Anavex Life Sciences on 8 of the 14 factors compared between the two stocks.

How does Spruce Biosciences compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Greenwich LifeSciences presently has a consensus target price of $47.50, suggesting a potential upside of 107.79%. Spruce Biosciences has a consensus target price of $190.60, suggesting a potential upside of 237.35%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Greenwich LifeSciences has higher earnings, but lower revenue than Spruce Biosciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A
Spruce Biosciences	$4.91M	15.76	-$38.97M	-$51.72	N/A

In the previous week, Greenwich LifeSciences had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for Greenwich LifeSciences and 1 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.46 beat Greenwich LifeSciences' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spruce Biosciences' return on equity of -203.99% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%
Spruce Biosciences	N/A	-203.99%	-127.96%

Greenwich LifeSciences has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.26, suggesting that its stock price is 226% more volatile than the S&P 500.

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Spruce Biosciences beats Greenwich LifeSciences on 10 of the 14 factors compared between the two stocks.

How does Spruce Biosciences compare to AC Immune?

AC Immune (NASDAQ:ACIU) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spruce Biosciences has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	67.53	-$85.03M	-$0.82	N/A
Spruce Biosciences	$4.91M	15.76	-$38.97M	-$51.72	N/A

AC Immune presently has a consensus target price of $7.50, suggesting a potential upside of 162.24%. Spruce Biosciences has a consensus target price of $190.60, suggesting a potential upside of 237.35%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, AC Immune had 9 more articles in the media than Spruce Biosciences. MarketBeat recorded 10 mentions for AC Immune and 1 mentions for Spruce Biosciences. AC Immune's average media sentiment score of 1.06 beat Spruce Biosciences' score of 0.46 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spruce Biosciences has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Spruce Biosciences	N/A	-203.99%	-127.96%

AC Immune has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.26, suggesting that its stock price is 226% more volatile than the S&P 500.

Summary

Spruce Biosciences beats AC Immune on 9 of the 16 factors compared between the two stocks.

How does Spruce Biosciences compare to Amarin?

Amarin (NASDAQ:AMRN) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

22.3% of Amarin shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amarin has higher revenue and earnings than Spruce Biosciences. Amarin is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.47	-$38.80M	-$0.65	N/A
Spruce Biosciences	$4.91M	15.76	-$38.97M	-$51.72	N/A

Amarin presently has a consensus target price of $12.00, suggesting a potential downside of 20.27%. Spruce Biosciences has a consensus target price of $190.60, suggesting a potential upside of 237.35%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Spruce Biosciences had 1 more articles in the media than Amarin. MarketBeat recorded 1 mentions for Spruce Biosciences and 0 mentions for Amarin. Spruce Biosciences' average media sentiment score of 0.46 beat Amarin's score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Neutral
Spruce Biosciences	Neutral

Spruce Biosciences has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Spruce Biosciences	N/A	-203.99%	-127.96%

Amarin has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500.

Summary

Spruce Biosciences beats Amarin on 11 of the 17 factors compared between the two stocks.

Get Spruce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRB vs. The Competition

Export

Metric	Spruce Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$77.63M	$971.54M	$6.26B	$12.13B
Dividend Yield	N/A	4.84%	2.78%	5.20%
P/E Ratio	-1.09	1.56	20.68	25.39
Price / Sales	15.76	121.65	534.00	75.98
Price / Cash	N/A	20.07	43.29	53.47
Price / Book	1.42	7.72	9.96	6.83
Net Income	-$38.97M	-$3.68M	$3.55B	$333.36M
7 Day Performance	-1.36%	57.31%	3.49%	3.10%
1 Month Performance	-14.41%	49.35%	4.14%	7.12%
1 Year Performance	920.78%	101.65%	41.81%	41.28%

Spruce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRB Spruce Biosciences	2.3678 of 5 stars	$56.50 -0.1%	$190.60 +237.3%	N/A	$77.63M	$4.91M	N/A	20	Upcoming Earnings
RZLT Rezolute	2.0983 of 5 stars	$3.29 -0.3%	$8.00 +143.2%	N/A	$314.85M	N/A	N/A	40	Upcoming Earnings
AVXL Anavex Life Sciences	2.2261 of 5 stars	$3.36 -1.5%	$21.33 +534.9%	N/A	$311.38M	N/A	N/A	40	Upcoming Earnings
GLSI Greenwich LifeSciences	1.025 of 5 stars	$22.30 +1.5%	$47.50 +113.0%	N/A	$308.97M	N/A	N/A	3	News Coverage Analyst Upgrade
ACIU AC Immune	2.6176 of 5 stars	$3.01 -1.3%	$7.50 +149.2%	N/A	$306.34M	$3.70M	N/A	140	Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRB) was last updated on 5/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spruce Biosciences (SPRB) Competitors

SPRB vs. RZLT, AVXL, GLSI, ACIU, and AMRN

How does Spruce Biosciences compare to Rezolute?

Summary

How does Spruce Biosciences compare to Anavex Life Sciences?

Summary

How does Spruce Biosciences compare to Greenwich LifeSciences?

Summary

How does Spruce Biosciences compare to AC Immune?

Summary

How does Spruce Biosciences compare to Amarin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spruce Biosciences (SPRB) Competitors

SPRB vs. RZLT, AVXL, GLSI, ACIU, and AMRN

How does Spruce Biosciences compare to Rezolute?

Do analysts rate RZLT or SPRB?

Which has more risk & volatility, RZLT or SPRB?

Is RZLT or SPRB more profitable?

Does the media favor RZLT or SPRB?

Which has higher earnings & valuation, RZLT or SPRB?

Do insiders & institutionals have more ownership in RZLT or SPRB?

Summary

How does Spruce Biosciences compare to Anavex Life Sciences?

Do analysts recommend SPRB or AVXL?

Which has better earnings and valuation, SPRB or AVXL?

Does the media favor SPRB or AVXL?

Is SPRB or AVXL more profitable?

Which has more volatility and risk, SPRB or AVXL?

Do institutionals & insiders have more ownership in SPRB or AVXL?

Summary

How does Spruce Biosciences compare to Greenwich LifeSciences?

Do analysts rate GLSI or SPRB?

Which has stronger valuation and earnings, GLSI or SPRB?

Does the media prefer GLSI or SPRB?

Is GLSI or SPRB more profitable?

Which has more risk & volatility, GLSI or SPRB?

Do insiders and institutionals hold more shares of GLSI or SPRB?

Summary

How does Spruce Biosciences compare to AC Immune?

Do insiders and institutionals hold more shares of ACIU or SPRB?

Which has stronger valuation and earnings, ACIU or SPRB?

Do analysts rate ACIU or SPRB?

Does the media prefer ACIU or SPRB?

Is ACIU or SPRB more profitable?

Which has more risk & volatility, ACIU or SPRB?

Summary

How does Spruce Biosciences compare to Amarin?

Do institutionals and insiders hold more shares of AMRN or SPRB?

Which has higher valuation & earnings, AMRN or SPRB?

Do analysts rate AMRN or SPRB?

Does the media prefer AMRN or SPRB?

Is AMRN or SPRB more profitable?

Which has more risk and volatility, AMRN or SPRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB vs. The Competition

Spruce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools